Taro Pharmaceutical Industries Ltd (NYSE:TARO)
| 62.82 Delayed Data As of Aug 07 |  -0.43 / -0.68%Today’s Change | 56.07 Today|||52-Week Range 99.69 | -28.56% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Generic | MARKET CAP $2.4B |
Company Description
Taro Pharmaceutical Industries Ltd. is engaged in the development, manufacturing, and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada, and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company was founded in 1950 and is headquartered in Haifa Bay, Israel.
Contact Information
Taro Pharmaceutical Industries Ltd. 14 Hakitor Street Haifa Bay Haifa 26247 |
Employees
Shareholders
| Other institutional | 6.92% |
| Mutual fund holders | 5.50% |
| Individual stakeholders | 11.85% |
Top Executives
| Uday Vijaykumar Baldota | Chief Executive Officer & Director |
| Itamar Karsenti | Vice President & Head-Operations |
| Daphne Yan Huang | VP, Chief Financial & Accounting Officer |
| Avi Avramoff | Global Vice President-Research & Development |
| Richard Glaze | Vice President-Information Technology |
